Sign in Subscribe
Americans

President Trump Signs Executive Order to Lower Prescription Drug Prices in the US

Strategic Insights

— 2 min read

President Donald J. Trump has signed a new Executive Order aimed at addressing the long-standing issue of disparate drug pricing in the US, where Americans pay significantly more for prescription drugs than citizens in other developed countries. The order, which introduces a "Most-Favored-Nation" (MFN) pricing model, targets unfair international pricing practices that inflate costs for American consumers. According to data referenced by the Administration, U.S. prices are often more than three times higher than those in other OECD nations, even after accounting for discounts provided by manufacturers within the US.

Key Takeaways:

  • The Executive Order aims to bring prescription drug prices in the US in line with those paid by comparable developed nations, with the goal of reducing healthcare costs for American consumers.
  • The order targets unfair international pricing practices that inflate costs for American consumers, with US prices often more than three times higher than those in other OECD nations.
  • The Administration argues that while the US comprises less than five percent of the world's population, it funds approximately 75% of global pharmaceutical profits.
  • The order instructs the U.S. Trade Representative and the Secretary of Commerce to take action against foreign countries engaging in practices that undercut market prices and drive up prices in the US.
  • The Administration will communicate price targets to pharmaceutical manufacturers, establishing that America should receive the most favorable pricing.
  • The Secretary of Health and Human Services (HHS) will establish a mechanism allowing American patients to purchase their drugs directly from manufacturers who agree to sell at an MFN price, bypassing middlemen.
  • If drug manufacturers fail to offer MFN pricing, the HHS Secretary will propose rules to impose such pricing and take other measures to reduce prescription drug costs and curtail anticompetitive practices.

Statistics:

  • U.S. prices for prescription drugs are often more than three times higher than those in other OECD nations, even after accounting for discounts provided by manufacturers within the US (administered data).
  • The US comprises less than five percent of the world's population, but funds approximately 75% of global pharmaceutical profits (administered data).
  • The Executive Order targets practices that inflate costs for American consumers, with the aim of reducing healthcare costs for American consumers (Executive Order).
  • The order instructs the U.S. Trade Representative and the Secretary of Commerce to take action against foreign countries engaging in practices that undercut market prices and drive up prices in the US, within 180 days (Executive Order).
  • The Administration will communicate price targets to pharmaceutical manufacturers, establishing that America should receive the most favorable pricing, within 120 days (Executive Order).
  • The Secretary of Health and Human Services (HHS) will establish a mechanism allowing American patients to purchase their drugs directly from manufacturers who agree to sell at an MFN price, within 180 days (Executive Order).

Sources:

  • White House Fact Sheet: "Fact Sheet: President Donald J. Trump Announces Actions to Put American Patients First by Lowering Drug Prices and Stopping Foreign Free-Riding on American Pharmaceutical Innovation" (no date provided)

Read more